Common Contracts
4 similar Assignment and Assumption Agreement contracts by Avenue Therapeutics, Inc.
EX-10.1 2 s102626_ex10-1.htm EHIBIT 10-1 CONFIDENTIAL TREATMENT REQUESTED. Confidential portions of this document have been redacted and have been separately filed with the Commission. Exhibit No. 10.1 Asset Transfer and License AgreementAssignment and Assumption Agreement • May 5th, 2020 • New York
This Asset Transfer and License Agreement (the “Agreement”), is entered into as of February 17, 2015 (the “Effective Date”), by and between Revogenex Ireland Limited, an Irish limited company (“Revogenex”), and Coronado Biosciences, Inc., a Delaware corporation (“Coronado”). Coronado and Revogenex are both referred to herein as “Parties” or each individually, as a “Party.”
Asset Transfer and License AgreementAssignment and Assumption Agreement • March 13th, 2017 • Avenue Therapeutics, Inc. • Pharmaceutical preparations • New York
This Asset Transfer and License Agreement (the “Agreement”), is entered into as of February 17, 2015 (the “Effective Date”), by and between Revogenex Ireland Limited, an Irish limited company (“Revogenex”), and Coronado Biosciences, Inc., a Delaware corporation (“Coronado”). Coronado and Revogenex are both referred to herein as “Parties” or each individually, as a “Party.”
Asset Transfer and License AgreementAssignment and Assumption Agreement • January 12th, 2017 • Avenue Therapeutics, Inc. • Pharmaceutical preparations • New York
This Asset Transfer and License Agreement (the “Agreement”), is entered into as of February 17, 2015 (the “Effective Date”), by and between Revogenex Ireland Limited, an Irish limited company (“Revogenex”), and Coronado Biosciences, Inc., a Delaware corporation (“Coronado”). Coronado and Revogenex are both referred to herein as “Parties” or each individually, as a “Party.”
Asset Transfer and License AgreementAssignment and Assumption Agreement • February 18th, 2016 • Avenue Therapeutics, Inc. • Pharmaceutical preparations • New York
This Asset Transfer and License Agreement (the “Agreement”), is entered into as of February 17, 2015 (the “Effective Date”), by and between Revogenex Ireland Limited, an Irish limited company (“Revogenex”), and Coronado Biosciences, Inc., a Delaware corporation (“Coronado”). Coronado and Revogenex are both referred to herein as “Parties” or each individually, as a “Party.”
